These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 12522893

  • 1. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E, Robles NR, Grois J, Barquero A, Pérez Miranda M.
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [Abstract] [Full Text] [Related]

  • 2. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
    Napoli C, Omboni S, Borghi C, ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group.
    J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T.
    Cardiovasc Diabetol; 2007 Apr 03; 6():12. PubMed ID: 17407587
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R, COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators.
    Am J Hypertens; 2005 Nov 03; 18(11):1482-8. PubMed ID: 16280286
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
    Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B.
    Blood Press Monit; 2002 Apr 03; 7(2):135-42. PubMed ID: 12048432
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension.
    Forslund T, Franzén P, Backman R.
    J Intern Med; 1991 Dec 03; 230(6):511-7. PubMed ID: 1836220
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.
    Circulation; 2005 Mar 01; 111(8):1012-8. PubMed ID: 15723979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.